HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.

AuthorsKashef Ijaz, Peter D McElroy, John Jereb, Thomas R Navin, Kenneth G Castro
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 44 Issue 3 Pg. 464-5; author reply 465 (Feb 01 2007) ISSN: 1537-6591 [Electronic] United States
PMID17205462 (Publication Type: Comment, Letter)
Chemical References
  • Antitubercular Agents
  • Pyrazinamide
  • Rifampin
Topics
  • Antitubercular Agents (adverse effects)
  • Drug Administration Schedule
  • Humans
  • Liver (drug effects, pathology)
  • Practice Guidelines as Topic
  • Pyrazinamide (adverse effects)
  • Rifampin (adverse effects)
  • Treatment Outcome
  • Tuberculosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: